Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock	Additional paid-in capital Cumulative Effect, Period of Adoption, Adjustment	Additional paid-in capital	Accumulated deficit Cumulative Effect, Period of Adoption, Adjustment	Accumulated deficit	Cumulative Effect, Period of Adoption, Adjustment	Total
Balance at Dec. 31, 2020	$ 161		$ 1,528,535		$ (1,466,056)		$ 62,640
Balance (in shares) at Dec. 31, 2020	160,616,675
Increase (Decrease) in Stockholders' Equity (Deficit)
Issuance of common stock related to share-based awards and employee stock purchase plan	$ 1		2,229				2,230
Issuance of common stock related to share-based awards and employee stock purchase plan (in shares)	1,314,337
Share-based compensation expense related to share-based awards and employee stock purchase plan			5,396				5,396
Net income					39,926		39,926
Balance at Mar. 31, 2021	$ 162		1,536,160		(1,426,130)		110,192
Balance (in shares) at Mar. 31, 2021	161,931,012
Balance at Dec. 31, 2021	$ 162	$ (110,217)	1,543,357	$ 66,167	(937,608)	$ (44,050)	$ 605,911
Balance (in shares) at Dec. 31, 2021	162,036,461						162,036,461
Increase (Decrease) in Stockholders' Equity (Deficit)
Issuance of common stock related to share-based awards and employee stock purchase plan	$ 1		1,520				$ 1,521
Issuance of common stock related to share-based awards and employee stock purchase plan (in shares)	1,087,966
Share-based compensation expense related to share-based awards and employee stock purchase plan			6,089				6,089
Repurchases of common stock	$ (8)		(90,481)				$ (90,489)
Repurchases of common stock (in shares)	(8,009,272)						(8,000,000.0)
Net income					38,801		$ 38,801
Balance at Mar. 31, 2022	$ 155		$ 1,350,268		$ (832,640)		$ 517,783
Balance (in shares) at Mar. 31, 2022	155,115,155						155,115,155